Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Thalidomide’s promising future in fighting cancer explored in Mayo Clinic proceedings

13.07.2004


From the late 1950s to the end of 1961, thalidomide was a popular sedative and treatment for morning sickness until it was discovered to cause fetal malformations, which proved fatal within the first year of life in 40 percent of affected infants.
The drug was never marketed in the United States or approved by the U.S. Food and Drug Administration. But researchers recognized the drug’s properties might have cancer-fighting potential. This possibility has driven promising studies into thalidomide’s role in fighting blood disorders, such as multiple myeloma, a deadly cancer for which there is no cure. Mayo Clinic Proceedings’ July issue offers four studies that have probed thalidomide’s promising future after its tragic past.

"The most common indication for thalidomide use today is multiple myeloma and related plasma cell disorders," says S. Vincent Rajkumar, M.D., a hematologist at Mayo Clinic in Rochester, in a commentary article in the July issue of Mayo Clinic Proceedings. "Thalidomide represents a new era in therapy for this incurable and fatal malignancy."


But, says Dr. Rajkumar, one of the top researchers into thalidomide’s role in multiple myeloma, "Clinical trials eventually will determine whether thalidomide will be used as an anticancer agent in the long term or will be pushed into retirement by one or more safer analogues."

The July issue of Mayo Clinic Proceedings includes studies and editorials regarding thalidomide and myeloma:

Mayo Clinic researchers present findings in a long-term follow-up of patients with monoclonal gammopathy of undetermined significance (241 patients were examined at Mayo Clinic from 1956 to 1970) and found that the risk of progression to multiple myeloma or related cancer is indefinite and persists even after more than 30 years of follow-up. In an editorial, Joan Bladé, M.D., a hematologist at Hospital Clínic IDIBAPS in Barcelona, Spain, writes that Robert Kyle, M.D., a Mayo Clinic hematologist who led the study, first recognized the possibility of malignant transformation of monoclonal gammopathy. Because of Dr. Kyle’s detailed studies, physicians have learned about the actual outcome of persons with monoclonal gammopathy of undetermined significance, Bladé writes.

Mayo Clinic researchers report their findings in patients who’ve had relapses in multiple myeloma, noting that the response duration of the follow-up treatment or salvage therapy decreased. The researchers said this must be remembered when making treatment decisions for these patients and must be factored in when assessing the efficacy of new therapies.

Researchers from Dana-Farber Cancer Institute in Boston; Celgene Corporation in Warren, N.J.; St. Vincents Catholic Medical Center in New York; and H. Lee Moffitt Cancer Center in Tampa studied the dosage of thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation. They report that the optimal thalidomide dose varies and should be based on individual patients to ensure that it is well tolerated and a response is achieved.

When thalidomide is used alone or combined with prednisone, it can also be an effective frontline treatment for symptomatic anemia or low platelets in patients with myelofibrosis with myeloid metaplasia, a chronic form of leukemia. The Mayo Clinic College of Medicine researchers outline their findings regarding 36 patients. In an editorial about this study, Richard Silver, M.D., of New York-Presbyterian Hospital-Weill Cornell Medical Center in New York, writes that the results provide an important therapeutic contribution in terms of quality of life.

John Murphy | EurekAlert!
Further information:
http://www.mayo.edu

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

Im Focus: Like a wedge in a hinge

Researchers lay groundwork to tailor drugs for new targets in cancer therapy

In the fight against cancer, scientists are developing new drugs to hit tumor cells at so far unused weak points. Such a “sore spot” is the protein complex...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Magnetic nano-imaging on a table top

20.04.2018 | Physics and Astronomy

Start of work for the world's largest electric truck

20.04.2018 | Interdisciplinary Research

Atoms may hum a tune from grand cosmic symphony

20.04.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>